Standard Dental Labs Buys Dr. Tooth, Revenue Base Doubles

Standard Dental Labs Inc. (OTCQB: TUTH) announced on Oct. 2, 2026 that it acquired substantially all of the operating assets of Dr. Tooth, LLC, the dental laboratory business also known as Sheen Dental Laboratory and Hansen Incarnati. The company said the acquired business adds just over $800,000 in annualized revenue, which combined with its previously stated roughly $822,000 base for existing operations takes the estimated annualized revenue base to more than $1.6 million.

Context — Why the Dr. Tooth Acquisition Matters Now

The report gives the clearest comparable available: SDL's own prior estimate of approximately $822,000 in annualized revenue for its existing operations. Adding just over $800,000 in acquired revenue takes the combined base past $1.6 million, which the company describes as nearly double the prior figure.

That is a doubling of the revenue base through a single transaction rather than through organic account growth, and the company frames it as part of a deliberate consolidation strategy. SDL says it is building a Florida-focused dental laboratory group, buying laboratories and concentrating production in regional facilities.

What triggered the move now is the availability of the Dr. Tooth assets. The report does not disclose the negotiation timeline, the asking price or how long the business was for sale.

The operational catalyst matters more than the headline revenue. SDL says the acquired business currently outsources production to China, and the company plans to move that work to its Sarasota facility. Bringing production in-house is the mechanism the company expects to use to improve quality control, communication with dentists and utilization of the Sarasota plant.

This is a small-cap over-the-counter equity, so the macro backdrop is less about rates than about deal execution. The report does not tie the transaction to any financing market condition, and the company did not disclose the cash portion of the consideration.

Data — What the Numbers Show

The revenue figures in the report are management estimates of current operating levels extended over twelve months. They are not guidance for reported calendar 2026 revenue, and the company says so directly.

Metric	Before acquisition	After acquisition
Estimated annualized revenue	~$822,000	More than $1.6 million
Acquired business contribution	—	Just over $800,000
Management rebuild target	—	More than $1.1 million

The target figure is the number worth isolating. SDL believes the acquired business can be rebuilt to more than $1.1 million in annualized revenue, roughly $300,000 above the just over $800,000 it currently generates. The company conditions that on retaining current accounts, recovering former customers and completing the production transition.

The consideration was structured as an asset purchase using a combination of cash and SDL common stock. The stock component includes performance conditions tied to retained customer revenue, which links part of the seller's payout to whether accounts stay with the business after the move.

The report does not disclose the cash amount, the number of shares issued, the valuation multiple paid or the size of the retention thresholds. The company also did not state whether the transaction required any external financing.

Analysis — What It Means for SDL and Dental Lab Peers

The second-order effect sits in the cost line, not the revenue line. Moving production from an overseas supplier to Sarasota converts an outsourced variable cost into internal capacity utilization. If the acquired volume fills existing idle time at the facility, the incremental margin on that work should exceed the margin on work the company pays a third party to produce.

The customer-retention structure is the main risk. The acquired accounts are dental practices that have been buying restorations produced in China, and the pitch to keep them is domestic production with direct access to the people making the restorations. Practices that chose the outsourced model on price may not all follow the work to Florida.

A counter-argument worth weighing: the company is simultaneously integrating a business, relocating its production and asking customers to accept a change in how their restorations are made. Each of those is a source of attrition, and the report offers no retention data to show how the existing customer base has responded.

There is also the question of whether the acquired management team stays. The report says SDL's management will include Denis Thaxton and Gavin White, the existing Dr. Tooth management team, which keeps the customer relationships inside the combined company during the transition.

Positioning is difficult to read from the report alone. This is an OTCQB-listed micro-cap, and the report gives no trading volume, share price, market capitalization or shareholder data. What the report does establish is that SDL is paying with stock as well as cash, which puts existing holders' ownership in the combined company on the line.

Outlook — What to Watch Next

The first checkpoint is retention. SDL's more than $1.1 million rebuild target depends on holding current accounts and winning back former customers, so any subsequent disclosure on account counts or revenue run-rate is the clearest signal on whether the thesis is working.

The second is the production move. The company says the work currently outsourced to China will transfer to Sarasota, and the timing of that transfer will determine when the facility utilization benefit shows up. The report does not give a completion date.

The third is the stock-based consideration. The performance conditions tied to retained customer revenue mean the eventual share issuance depends on how much business survives the transition, and the company has not disclosed the thresholds.

SDL has also signaled that acquisitions are its growth model, so the next transaction, if there is one, would test whether the Sarasota consolidation approach scales beyond a single deal.

Frequently Asked Questions

What does the Dr. Tooth acquisition mean for SDL shareholders?

The transaction roughly doubles SDL's estimated annualized revenue base, from approximately $822,000 to more than $1.6 million, on management's estimates. Part of the purchase price is SDL common stock with performance conditions tied to retained customer revenue, so the final share count depends on how much of the acquired business is kept. The company did not disclose the cash amount, share count or valuation multiple paid.

Why is Standard Dental Labs moving production from China to Sarasota?

The company said domestic production can strengthen quality control and communication with dentists, help recover former customer relationships and increase utilization of the Sarasota facility. Adding volume to existing infrastructure is expected to improve the facility's profitability as integration progresses. The report does not give a timeline for completing the transition or a cost estimate for the move.

What is SDL's revenue target for the acquired business?

Management believes it can rebuild the acquired business to more than $1.1 million in annualized revenue, up from the just over $800,000 it generates at current operating levels. That objective depends on retaining current accounts, recovering customers and successfully transitioning production. The company cautions that its annualized figures are estimates of operating activity extended over twelve months, not a forecast of revenue to be reported for calendar 2026.

Bottom Line

SDL is paying cash and stock to nearly double its estimated revenue base, but the return depends on customers following their work from China to Florida.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.